These dual compounds induce apoptosis and autophagy in cancer cell lines and cytotoxicity in xenograft tumor models in vivo
Real patient considerations and common questions Beyond the specs and pricing, real-world experience with Pomegranate Health reveals practical considerations that matter for day-to-day treatment

Major Criteria Family history of vEDS with a documented causative variant in COL3A1 Arterial rupture at a young age Spontaneous sigmoid colon perforation in the absence of known diverticular disease or other bowel pathology Uterine rupture during the third trimester in the absence of previous C-section and/or severe peripartum perineum tears Carotid-cavernous sinus fistula (CCSF) formation in the absence of trauma Minor Criteria Bruising unrelated to identified trauma and/or in unusual sites such as the cheeks and back Thin, translucent skin with increased venous visibility Characteristic facial appearance Spontaneous pneumothorax Acrogeria Talipes equinovarus Congenital hip dislocation Hypermobility of small joints Tendon and muscle rupture Keratoconus Gingival recession and gingival fragility Early-onset varicose veins (under age 30 and starting before pregnancy if female) If a person meets the diagnostic criteria for aEDS, genetic testing should be done to confirm the diagnosis

3.5 Rapid Weight Loss and Lean Mass Reduction Weight loss during GLP-1 therapy includes: Adipose tissue Lean body mass Data from obesity trials indicate that without resistance training and adequate protein intake, a meaningful proportion of weight lost may be lean mass. Reduced protein intake may indirectly influence: Iron intake Zinc intake B12 intake This creates a secondary nutrient risk pathway unrelated to absorption but related to dietary composition
Here is the timeline of average weight loss: 12 weeks: -20.12 pounds 24 weeks: -35.67 pounds 36 weeks: -47.33 pounds 52 weeks (1 year): -52.28 pounds 72 weeks (18 months): -62.79 pounds (-26.54% body weight) These are averages, which means individual results varied